| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Investigations |
1 Nuclear Medicine Division, Ghent University Hospital, Ghent, Belgium
2 Department of Medical Physics, Ghent University, Ghent, Belgium
3 Division of Interventional Radiology, Ghent University Hospital, Ghent, Belgium
4 Division of Gastroenterology, Ghent University Hospital, Ghent, Belgium
5 Department of Nuclear Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
The aim of this study was to investigate the pharmacokinetics, organ dosimetry, and toxicity after the intraarterial administration of 188Re-labeled 4-hexadecyl-1,2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol/lipiodol (188Re-HDD/lipiodol) for palliative treatment of hepatocellular carcinoma (HCC). A secondary objective was to document the response. Methods: A mean activity of 3.60 GBq 188Re-HDD/lipiodol (range, 1.86–4.14 GBq) was administered to 11 patients (16 treatment sessions) via a transfemoral catheter. The pharmacokinetic and dosimetric data were collected by means of venous blood samples, urine collections, and 4 or 5 
-scintigraphies over 76 h. Absorbed doses to the various organs were calculated according to the MIRD formalism, using the MIRDOSE3.1 software. The toxicity was assessed until 6 wk after administration by means of the Common Toxicity Criteria scale. The response was evaluated on MRI and by monitoring of the tumor marker. Results: A fast blood clearance of the injected activity was observed with a calculated effective half-life of 7.6 ± 2.2 h (±SD) in blood. The predominant elimination of the activity was through urinary excretion with a mean renal clearance of 44.1% ± 11.7% (±SD) of the injected activity within the 76 h after administration. Fecal elimination was negligible. The calculated whole-body effective half-life was 14.3 ± 0.9 h (±SD). The absorbed dose to the liver tissue, the lungs, the kidneys, and the thyroid was 4.5 ± 1.9, 4.1 ± 1.2, 0.9 ± 0.7, and 0.3 ± 0.1 Gy, respectively. Treatment was well tolerated, except in 2 patients. One Child B patient experienced a worsening of his liver dysfunction (hyperbilirubinemia) and another patient experienced dyspnea and coughing. Response assessment on MRI showed 1 case of partial response, disease stabilization in 11 treatments, and progressive disease in 1 treatment. In 5 of 8 treatment sessions with an initially elevated 
-fetoprotein, a reduction (range, 19%–90%) was observed 6 wk later. Conclusion: After the intraarterial administration of 3.60 GBq 188Re-HDD/lipiodol, a fast clearance of the activity appearing in the blood is observed and the predominant elimination is through urinary excretion. The tolerance as well as the preliminary response rates of the present phase I study are encouraging.
Key Words: hepatocellular carcinoma • lipiodol • 188Re • radionuclide therapy • 4-hexadecyl-1,2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  W. J. G. Oyen, L. Bodei, F. Giammarile, H. R. Maecke, J. Tennvall, M. Luster, and B. Brans Targeted therapy in nuclear medicine current status and future prospects Ann. Onc., November 1, 2007; 18(11): 1782 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lambert, K. Bacher, K. De Keukeleire, P. Smeets, I. Colle, J. M. Jeong, H. Thierens, R. Troisi, F. De Vos, and C. Van de Wiele 188Re-HDD/Lipiodol for Treatment of Hepatocellular Carcinoma: A Feasibility Study in Patients with Advanced Cirrhosis J. Nucl. Med., August 1, 2005; 46(8): 1326 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Liepe, J. Kotzerke, and B. Lambert Advantage of 188Re-Radiopharmaceuticals in Hepatocellular Cancer and Liver Metastases J. Nucl. Med., August 1, 2005; 46(8): 1407 - 1408. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
